In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates.

Background: Increasing antibiotic resistance in Helicobacter pylori necessitates research on new active molecules. In 2017, delafloxacin, a new fluoroquinolone with chemical properties of activity under acidic conditions, was approved for treatment of community-acquired bacterial pneumonia and acute bacterial skin and soft-tissue infections. Mutations in gyrA are responsible for fluoroquinolone resistance, but certain clinical isolates of H.

Mutations Associated to Antibiotic-Resistant : It Is Time to Validate Sequencing Observations.

, a Gram-negative microaerophilic microorganism, is the only bacterial pathogen classified as a Class I carcinogen [...